SOLICITATION NOTICE
66 -- BWF5 Turnkey Diode Laser System
- Notice Date
- 8/27/2012
- Notice Type
- Presolicitation
- NAICS
- 335129
— Other Lighting Equipment Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-120188-KM
- Archive Date
- 9/26/2012
- Point of Contact
- Karri L. Mares, Phone: 3014357774, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
maresk@mail.nih.gov, cr214i@nih.gov
(maresk@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6076, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI) plans to procure on a sole source basis the brand name BWF5 Turnkey Diode Laser System (Model BWF5-690-8-600-0.3) from B&W Tek, 19 Shea Way, Newark, DE 19713. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The North American Industry Classification System code is 335129 and the business size standard is 500 employees. Delivery Date shall be no more than 90 days from date of award. It has been determined that there is no opportunity to acquire green products or services under this contract. The Molecular Imaging Program (MIP) conducts research in designing, developing and testing new novel targeted imaging agents for the detection and characterization of cancer. These imaging agents include tissue-specific MRI, PET, radionuclide, and optical probes. The MIP has developed a new method of treating cancer with light that will kill cancer cells but spare non cancer cells. It uses light of low energy but of a specific wavelength that is absorbed by cells which quickly are selectively killed. It is based on a monoclonal antibody conjugated to a photosensitizing agent known as IR-700. IR-700 absorbs light at 690nm and directly heats cells to which the antibody is bound. The process is known as photoimmunotherapy or PIT. The NCI requires the purchase of a Turnkey Diode laser system from B&W Tek, Inc. This diode laser system shall be used in an upcoming clinical trial with Johns Hopkins University. The NCI has established collaborations with Johns Hopkins University to conduct the first human trial of PIT in patients with Head and Neck cancers. The light, however, must be of a particular wavelength and sufficient energy. This diode laser will provide specific wavelength light (690nm) that will be used with Johns Hopkins surgical instruments to kill Head and Neck tumors in selected patients whose cancers have recurred after standard therapy. Thus, this diode laser is pivotal to the ongoing translation of PIT into clinical use. Salient Characteristics of the B&W Tek, Inc Turnkey Diode Laser System - Emit specific wavelength - 690nm - Maximum power requirement - 8W - Two meter long 600um fiber at 0.37NA at 2X SMA 905 connector - Portable high powered diode laser - Stand alone and self-contained laser system - Microcontroller - LCD touch screen This diode laser is pivotal to the ongoing translation of PIT into clinical use. The only manufacturer that makes diode lasers that emits light at the appropriate wavelength (690nm) is B&W. This device has only recently become available and will meet the needs of this clinical trial. It will be used with John's Hopkins surgical instruments to kill Head and Neck tumors in selected patients whose cancers have recurred after standard therapy. B&W is the only known manufacturer who produces this diode laser at the 690mm wavelength required. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on September 11, 2011. No electronic capability statements will be accepted (i.e. email or fax), an original and one copy must be sent to the NCI Office of Acquisitions at the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Karri Mares, Contract Specialist at maresk@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the System for Award Management (SAM) at www.sam.gov. No collect calls will be accepted. Please reference solicitation number NCI-120188-KM on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-120188-KM/listing.html)
- Record
- SN02856653-W 20120829/120828000131-7cfeaad23a8d67eb5a971e8c98894779 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |